Breaking News Headlines Today | Ground News

See every side of every news story

Express Pharma image

News from Express Pharma

Ground News rates Express Pharma’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Express Pharma’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Express Pharma

Where is Express Pharma located?Express Pharma's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Express Pharma News

Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump — ANGELA WEISS/AFP via Getty Images via Getty Images

Drug Prices · United States

Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump

50% Center coverage: 320 sources

Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other drugmakers under the threat of tariffs.See the Story

Lupin Strengthens Its Global Specialty Ophthalmology Business with Acquisition of VISUfarma From GHO Capital

Switzerland · Switzerland

Lupin Strengthens Its Global Specialty Ophthalmology Business with Acquisition of VISUfarma From GHO Capital

42% Right coverage: 12 sources

LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the…See the Story

Ozempic Injection: CDSCO Approves Breakthrough Diabetes Treatment for Indian Market

Diabetes · India

Ozempic Injection: CDSCO Approves Breakthrough Diabetes Treatment for Indian Market

75% Right coverage: 4 sources

The Central Drugs Standard Control Organisation has approved Novo Nordisk's Ozempic, a groundbreaking once-a-week injection for Type 2 diabetes patients in India. Available via prescription, the semaglutide injection not only aids in diabetes management but also reduces cardiovascular and kidney disease risks, setting new standards in diabetes care.See the Story

Breaking News Topics Related to Express Pharma